Skip to main content
NCBI home page
Current Therapeutic Research, Clinical and Experimental logoLink to Current Therapeutic Research, Clinical and Experimental
. 2005 May;66(3):238–246. doi: 10.1016/j.curtheres.2005.06.001

Pharmacokinetic properties of pravastatin in Mexicans: An open-label study in healthy adult volunteers

Yesenia Escobar 1, Caterina R Venturelli 1, Carlos Hoyo-Vadillo 1,**
PMCID: PMC3964574  PMID: 24672127

Abstract

Background:

The pharmacokinetic properties of pravastatin, particularlyAUC and Cmax, are variable by population. A description of the pharmacokinetic properties of pravastatin in Mexican mestizos was not found in a search of MEDLINE/PubMed (key terms: pravastatin, Mexican, and pharmacokinetics; years: 1966–2005). Because Mexicans and Japanese have common ancestors (Mongoloid group), they also have a common gene pool. This gene pool was modified by genetic “bottlenecks” that occurred when these populations migrated to the Americas and when the Mexican population mixed with the Spanish population during the 16th and 17th centuries. Previous studies in Japanese subjects showed 5 main mutations on the hepatic drug transporter OATP-C, resulting in higher Cmax and AUC values compared with whites. In the Japanese population, the rates of expression of the *1b and *15 alleles were 46% and 15%, respectively.

Objective:

The aim of this study was to evaluate the pharmacokinetic propertiesof pravastatin in healthy Mexican mestizo volunteers and to compare them with those in white and Japanese populations described in the literature.

Methods:

This open-label, uncontrolled pilot study of the pharmacokineticproperties of pravastatin was conducted at the Division of Pharmacology, Center for Research and Advanced Studies, Mexico City, Mexico. Healthy, adult, Mexican volunteers received a single dose of pravastatin 10 mg PO (tablet). High-performance liquid chromatography was used to determine plasma pravastatin concentrations between 15 minutes and 12 hours after dosing.

Results:

Twenty-four subjects (15 women, 9 men; mean age, 30.6 years)participated in the study. The mean (SD) Cmax was 9.5 (2.4) ng/mL; Tmax, 0.8 (0.3) hours; AUC0−∞ 35.7 (19.7) ng/mL - h; t1/2, 2.7 (1.1) hours; and mean residence time, 3.1 (1.1) hours. One volunteer (4%) had an AUC value that differed substantially from the rest of the study population, producing a bimodal distribution of the pharmacokinetic parameters. No adverse events were observed or reported during the trial.

Conclusions:

In this small pilot study of the pharmacokinetic properties of pravastatin in Mexican mestizos, AUC was not statistically significantly different from previous studies, either in a white or Japanese population. However, we did not find the high values reported for Cmax in some Japanese subjects carrying recently reported mutations on the pravastatin transporter.

Key words: pravastatin, pharmacokinetics, oral administration, AUC

Full Text

The Full Text of this article is available as a PDF (556.9 KB).

References

  • 1.Quion J.A., Jones P.H. Clinical pharmacokinetics of pravastatin. Clin Pharmacokinet. 1994;27:94–103. doi: 10.2165/00003088-199427020-00002. [DOI] [PubMed] [Google Scholar]
  • 2.Hatanaka T. Clinical pharmacokinetics of pravastatin: Mechanisms of pharmacokinetic events. Clin Pharmacokinet. 2000;39:397–412. doi: 10.2165/00003088-200039060-00002. [DOI] [PubMed] [Google Scholar]
  • 3.Haruyama H., Kuwano H., Kinoshita T. Structure elucidation of the bioactive metabolites of ML-236B (mevastatin) isolated from dog urine. Chem Pharm Bull (Tokyo) 1986;34:1459–1467. doi: 10.1248/cpb.34.1459. [DOI] [PubMed] [Google Scholar]
  • 4.Prisant L.M. Preventing type II diabetes mellitus. J Clin Pharmacol. 2004;44:406–413. doi: 10.1177/0091270004263018. [DOI] [PubMed] [Google Scholar]
  • 5.Halstenson C.E., Triscari J., Devault A. Single-dose pharmacokinetics of pravastatin and metabolites in patients with renal impairment. J Clin Pharmacol. 1992;32:124–132. doi: 10.1002/j.1552-4604.1992.tb03816.x. [DOI] [PubMed] [Google Scholar]
  • 6.Jandeleit-Dahm K., Cao Z., Cox A.J. Role of hyperlipidemia in progressive renal disease: Focus on diabetic nephropathy. Kidney Int Suppl. 1999;71:S31–S36. doi: 10.1046/j.1523-1755.1999.07109.x. [DOI] [PubMed] [Google Scholar]
  • 7.Singhvi S.M., Pan H.Y., Morrison R.A., Willard D.A. Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects. Br J Clin Pharmacol. 1990;29:239–243. doi: 10.1111/j.1365-2125.1990.tb03626.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Nishizato Y., Ieiri I., Suzuki H. Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: Consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther. 2003;73:554–565. doi: 10.1016/S0009-9236(03)00060-2. [DOI] [PubMed] [Google Scholar]
  • 9.Castaneda-Hernandez G., Hoyo-Vadillo C., Palma-Aguirre J.A., Flores-Murrieta F.J. Pharmacokinetics of oral nifedipine in different populations. J Clin Pharmacol. 1993;33:140–145. doi: 10.1002/j.1552-4604.1993.tb03934.x. [DOI] [PubMed] [Google Scholar]
  • 10.Aldrete-Velasco J., Casanova J.M., Mejia P., Martinez P. Efficacy of pravastatin as a hypolipidemic agent in patients with polygenic hypercholesterolemia. Arch Med Res. 1992;23:117–122. [PubMed] [Google Scholar]
  • 11.Lisker R., Ramirez E., Briceno R.P. Gene frequencies and admixture estimates in four Mexican urban centers. Hum Biol. 1990;62:791–801. [PubMed] [Google Scholar]
  • 12.Lisker R., Ramirez E., Babinsky V. Genetic structure of autochthonous populations of Meso-America: Mexico. Hum Biol. 1996;68:395–404. [PubMed] [Google Scholar]
  • 13.Lisker R., Perez-Briceno R., Granados J. Gene frequencies and admixture estimates in a Mexico City population. Am J Phys Anthropol. 1986;71:203–207. doi: 10.1002/ajpa.1330710207. [DOI] [PubMed] [Google Scholar]
  • 14.K. Otter, C. Mignat. Determination of pravastatin in human plasma by high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl. 1998;708:235–241. doi: 10.1016/s0378-4347(97)00625-7. [DOI] [PubMed] [Google Scholar]
  • 15.Causon R. Validation of chromatographic methods in biomedical analysis. Viewpoint and discussion. J Chromatogr B Biomed Sci Appl. 1997;689:175–180. doi: 10.1016/s0378-4347(96)00297-6. [DOI] [PubMed] [Google Scholar]
  • 16.Akaike H. A new look at the statistical model identification. IEEE Trans Automat Contr. 1974;AC-19:716–723. [Google Scholar]
  • 17.Pan H.Y., DeVault A.R., Swites B.J. Pharmacokinetics and pharmacodynamics of pravastatin alone and with cholestyramine in hypercholesterolemia. Clin Pharmacol Ther. 1990;48:201–207. doi: 10.1038/clpt.1990.136. [DOI] [PubMed] [Google Scholar]
  • 18.Ogawa K., Hasegawa S., Udaka Y. Individual difference in the pharmacokinetics of a drug, pravastatin, in healthy subjects. J Clin Pharmacol. 2003;43:1268–1273. doi: 10.1177/0091270003257232. [DOI] [PubMed] [Google Scholar]
  • 19.Fukazawa I., Uchida N., Uchida E., Yasuhara H. Effects of grapefruit juice on pharmacokinetics of atorvastatin and pravastatin in Japanese. Br J Clin Pharmacol. 2004;57:448–455. doi: 10.1046/j.1365-2125.2003.02030.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Sugimoto K., Ohmori M., Tsuruoka S. Different effects of St John's wort on the pharmacokinetics of simvastatin and pravastatin. Clin Pharmacol Ther. 2001;70:518–524. doi: 10.1067/mcp.2001.120025. [DOI] [PubMed] [Google Scholar]
  • 21.Mazzu A.L., Lasseter K.C., Shamblen E.C. Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin. Clin Pharmacol Ther. 2000;68:391–400. doi: 10.1067/mcp.2000.110537. [DOI] [PubMed] [Google Scholar]

Articles from Current Therapeutic Research, Clinical and Experimental are provided here courtesy of Elsevier

RESOURCES